Breast cancer diagnostic system: Approved in Europe

Imperial Cancer Research Fund (London, U.K.) researchers and colleagues published in The Lancet the ability of BZET's Biofield Diagnostic System, which uses skin surface electropotential measurements, to discriminate between breast cancer and benign lesions as an alternative to tissue biopsy. Among 661 women undergoing breast biopsy, more than half of the biopsies could have been avoided by using the diagnostic, which works best in pre-menopausal women. ...